A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis

INTRODUCTION: YLB113 is a biosimilar of the reference product (RP), etanercept, under development for treatment of patients with moderate-to-severe rheumatoid arthritis (RA) and other approved indications. A phase 3 study was conducted in Europe, Japan, and India to compare the efficacy, safety, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Hisashi, Kamatani, Naoyuki, Tanaka, Yoshiya, Hibino, Toshihiko, Drescher, Edit, Sánchez-Bursón, Juan, Rettenbacher, Manfred, Bhatia, Girish, Gadve, Snehal, Shah, Chirag, Bakhle, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021908/
https://www.ncbi.nlm.nih.gov/pubmed/31833011
http://dx.doi.org/10.1007/s40744-019-00186-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021908/
https://www.ncbi.nlm.nih.gov/pubmed/31833011
http://dx.doi.org/10.1007/s40744-019-00186-3

Ejemplares similares